
OS Therapies Inc
OS Therapies Inc (OSTX)
WebsitePrice
Market cap
Next catalystMid-Q4 2026 UK initiation, following Phase 2b drug-product requalificationOST-HER2 — planned UK confirmatory Phase 3 · Trial initiationCompany release ↗
Cash
Chart & Events
Technology Summary
Scientific context
Detailed technology interpretation
Technology advantages
Clinical
Upcoming clinical milestones
PreINDP1P2P3FilingApproved
Other pipelines
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
OST-tADC-A
Folate receptor alpha (FRα)
PreINDP1P2P3FilingApproved
OST-tADC-FRA-H
Folate receptor alpha (FRα)
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved